Esmé SX Featured in Snatch Health’s Performance Player Spotlight — Fall 2025 Market Intelligence Report
September 2025
THE COMPANY
Chelsey Moss wants to do more than revolutionize sexual wellness — she wants to reclaim it. After years researching the nervous system’s role in human connection, Moss recognized a devastating truth: the $125 billion sexual wellness industry treats women’s bodies like machines to be hacked rather than intelligent systems to be honored. Her groundbreaking research paper, The Clitoral Mycelium: Reclaiming the Network of Feminine Intelligence, reframes the clitoris not as a button to push but as an interconnected network of 8,000 nerve endings that, when properly engaged, can regulate the entire autonomic nervous system. Esmé SX is building one of, if not the first biometric-responsive intimacy platforms that treats sexual wellness as an optimizable performance domain, not a problem to fix.
THE INNOVATION
Esmé SX abandons the “vibrator model” entirely, creating technology that reads and responds to real-time biometric signals — HRV, breath patterns, temperature, microvascular response — working with the body’s natural arousal patterns rather than overriding them. Multiple biosensors create a feedback loop that measures nervous system state, arousal mapping, parasympathetic activation, and tissue engagement. These signals generate synchronized thermoacoustic (temperature & sound) and haptic responses calibrated to each user’s unique arousal arc. Rather than predetermined patterns, the device responds dynamically to biological signals, strengthening mind-body connection and training the nervous system for enhanced pleasure over time. This isn’t about reaching climax faster; it’s about strengthening the coherence that makes profound pleasure possible. By treating sexual response as a biomarker for overall system health, Esmé SX transforms intimacy from entertainment into optimization.
THE VISION
Moss sees a future where sexual wellness is recognized as the third pillar of health, alongside nutrition and exercise. Where women track their arousal patterns to optimize hormonal health, where couples use biometric feedback to deepen intimacy, where pleasure is prescribed for stress relief and nervous system regulation. Esmé SX is building toward “Sexual Medicine 3.0” — a paradigm focused on optimization, enhancement, and expanded vitality, rather than focusing on and treating dysfunction.
THE VALIDATION
The sexual wellness market is projected to hit $125 billion by 2026, growing at 12.6% CAGR — faster than almost any other health vertical. Yet 61% of women see the connection between exercise and sexual wellness while only 2% use sexual wellness apps, revealing massive untapped demand for science-backed solutions. Esmé SX’s approach — treating pleasure as a performance metric rather than entertainment — positions them to capture the market that Dame, Maude, and others have begun to legitimize but haven’t yet optimized.
MARKET SIGNALS
It was proof things were shifting when Maude products landed in Sephora and Unbound broke onto Target shelves. But when Dame raised $7M in venture funding, becoming the first sex accessories company to raise institutional capital, it became clear that the sexual health market has moved from backroom shame to mainstream retail. Still, no one has claimed the performance optimization space as it relates to this market. The clitoris wasn’t even mapped until 1998, and we’re still discovering its role in overall health: neural stimulation boosts immune function, reduces cortisol, and improves sleep quality. The fact that tech giants remain terrified of the space (Meta and Google still shadow-ban women’s sexual wellness content while boldly promoting ED solutions) creates a massive opportunity for companies willing to go where Silicon Valley won’t. Esmé SX’s biometric approach positions them as the WHOOP of sexual wellness — data-driven, science-based, performance-focused.
By 2030, sexual wellness technology will merge with longevity medicine as science continues to validate the profound systemic benefits of optimized intimate health on hormones, cardiovascular function, and cellular aging, placing it alongside nutrition and exercise in preventive medicine for stress management, hormonal balance, and nervous system regulation. Insurance companies will cover biometric intimacy devices with the same ease they cover Viagra, recognizing that optimized sexual health reduces overall healthcare costs. Neural and vascular systems as sexual biomarkers will become standard health metrics alongside heart rate and sleep quality. Esmé SX’s tech could expand beyond personal pleasure into couples therapy (synchronized biometric feedback), medical treatment (orgasm therapy for chronic pain and PTSD), and hormonal patterns predicting and treating imbalance. They’re poised to successfully medicalize pleasure without pathologizing it and transform how we understand the connection between pleasure, performance, and overall system health in the process. Watch for partnerships with women’s health clinics, integration with cycle tracking apps, and eventually, FDA clearance for therapeutic applications.
QUOTE
“Sexual wellness isn’t entertainment. It’s health… We position sexual wellness as an active domain of health that can be measured, cultivated, and enhanced, much like cardiovascular fitness.”
— Chelsey Moss, Founder & CEO, Esmé SX
FACTS & FIGURES
3 biometric signals tracked in real time + number of patents filed
8,000 clitoral nerve endings engaged through network approach
1st known* platform to integrate sexual wellness with ANS optimization (*at time of publication)
Closing
Esmé SX is grateful to Ashleigh Marie Brown, Jillian Miranda, and the Snatch Health team for their work in producing this landmark report and for advancing the conversation on the future of women’s performance health.